Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Thiogenesis Therapeutics Corp ( (TSE:TTI) ) has shared an announcement.
Thiogenesis Therapeutics Corp announced positive interim results from its Phase 2 clinical trial of TTI-0102 for MELAS, showing biological proof-of-concept and biomarker improvement. The company plans to advance to a Phase 3 study in MELAS and adjust dosing protocols for future trials. Updates were also provided on their pipeline for Leigh syndrome and nephropathic cystinosis, with plans to initiate further trials and regulatory filings.
More about Thiogenesis Therapeutics Corp
Thiogenesis Therapeutics Corp is a clinical-stage biotechnology company focused on developing sulfur-based therapeutics for pediatric diseases, particularly those involving mitochondrial dysfunction.
Average Trading Volume: 15,836
Technical Sentiment Signal: Buy
Current Market Cap: C$39.91M
For detailed information about TTI stock, go to TipRanks’ Stock Analysis page.